Physician profile
Seth D Walker
NPI 1104935469
$12,333.32
in general payments reported to CMS, 2019-2025
29 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $96.11 · 2021: $196 · 2022: $118 · 2023: $636 · 2024: $448 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631 · Education: $33.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.70 |
| Education | $33.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $10,235.00 | 2019 | |
| Insmed, INC. | $466.78 | 2021-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals Lp | $270.52 | 2020-2025 | Fasenra, Tezspire, Tagrisso |
| Glaxosmithkline, LLC. | $269.21 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $147.38 | 2020-2024 | |
| Mylan Specialty L.P. | $119.75 | 2023 | Tobi Podhaler |
| United Therapeutics Corporation | $94.48 | 2021-2025 | Tyvaso, Remodulin, Orenitram |
| Grifols USA, LLC | $69.23 | 2023 | Prolastin-C Liquid, Xembify |
| Philips North America LLC | $63.59 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Bayer Healthcare Pharmaceuticals INC. | $51.36 | 2022-2025 | |
| Amgen INC. | $49.34 | 2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.42 | 2023-2025 | Ofev |
| Merck Sharp & Dohme LLC | $40.81 | 2023-2024 | Winrevair, Belsomra |
| Genzyme Corporation | $38.62 | 2024-2025 | |
| Tactile Systems Technology INC | $36.08 | 2025 | Nimbl, Flexitouch Plus |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $33.47 | 2024 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $33.23 | 2020-2022 | |
| Zoll Medical Corporation | $33.07 | 2020 | |
| Johnson & Johnson Health Care Systems INC. | $29.73 | 2023 | Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $29.43 | 2023 | Glassia |
| Novartis Pharmaceuticals Corporation | $27.61 | 2023 | |
| Mallinckrodt Hospital Products INC. | $24.45 | 2023 | Acthar |
| Chiesi USA, INC. | $24.39 | 2019 | |
| Viatris Specialty LLC | $21.04 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $19.73 | 2025 | Opsumit |
| Abbvie INC. | $18.89 | 2024 | |
| Gilead Sciences, INC. | $15.46 | 2022 | |
| Resmed Corp | $13.31 | 2022 | |
| Pulmonx Corporation | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.